Conference
A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of farletuzumab (MORAb-003) in combination with weekly paclitaxel in subjects with platinum-resistant or refractory relapsed ovarian cancer.
Authors
Elit L; Konner JA; Armstrong DK; Buck M; Dean A; Finkler NJ; Hulstine A; Schweizer C; Phillips M; Weil S
Volume
28
Pagination
pp. tps255-tps255
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2010
DOI
10.1200/jco.2010.28.15_suppl.tps255
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X